The global landscape of viral hepatitis is currently defined by a profound paradox. On one hand, the world has witnessed unprecedented medical and policy-driven victories that have significantly reduced transmission rates and mortality. On the other, the disease remains a formidable silent killer, claiming over a million lives annually and exposing deep-seated inequalities in global healthcare infrastructure.
According to the latest World Health Organization (WHO) report, released today at the World Hepatitis Summit, the fight against hepatitis B and C—the two strains responsible for 95% of hepatitis-related fatalities—stands at a critical juncture. While the trajectory of the disease is bending toward containment, the current pace of progress is insufficient to meet the ambitious 2030 elimination targets set by Member States.
The State of the Global Burden: A Statistical Snapshot
The data for 2024 reveals a sobering reality. Despite the availability of life-saving vaccines and curative treatments, approximately 287 million people are living with chronic hepatitis B or C. The human cost of this crisis is staggering: 1.34 million deaths in 2024 alone. Perhaps more alarming is the persistent rate of new infections, with roughly 4,900 people contracting the virus every day, totaling 1.8 million new cases annually.
The Geography of Vulnerability
The burden of the disease is not distributed equally. In 2024, the WHO African Region emerged as a primary concern, accounting for 68% of new hepatitis B infections. Yet, paradoxically, only 17% of newborns in that region received the crucial birth-dose vaccination, a gap that represents a massive failure in preventative public health.
For hepatitis C, the transmission dynamics are linked to specific social and behavioral factors. People who inject drugs account for 44% of new infections, highlighting an urgent need for the integration of harm reduction services into broader public health strategies.
The mortality concentration is equally telling. Ten nations—including Bangladesh, China, Ethiopia, Ghana, India, Indonesia, Nigeria, the Philippines, South Africa, and Viet Nam—account for 69% of global hepatitis B deaths. Hepatitis C deaths show a wider, yet still concentrated, footprint across ten countries, including major global powers like the United States, Japan, and the Russian Federation.
A Chronology of Progress: From 2015 to the Present
To understand where we are, we must look at the progress made since 2015, the benchmark year for global elimination efforts.
- 2015: The baseline year for current global tracking. Following the introduction of highly effective 12-week curative treatments for hepatitis C—which boast a 95% cure rate—the global health community began to reorganize its efforts.
- 2016: A pivotal moment occurred at the World Health Assembly, where Member States officially adopted the WHO’s viral hepatitis elimination targets. This signaled a shift from passive observation to active, coordinated policy implementation.
- 2016–2023: A period of sustained, albeit uneven, effort. The global community saw a 32% reduction in new hepatitis B infections and a 12% decline in hepatitis C-related deaths. Perhaps the most celebrated success is the prevalence of hepatitis B in children under five, which has plummeted to 0.6%, with 85 countries already hitting or exceeding the 2030 target of 0.1%.
- 2024: The release of the current report serves as a mid-term audit. It acknowledges the successes of the last decade while sounding a clarion call regarding the slow speed of progress toward the 2030 goals.
The Human and Systemic Barriers to Elimination
Why, with the tools to cure or prevent these diseases, are we still seeing millions of infections? The answer lies in the intersection of stigma, economic barriers, and systemic health failures.
The Diagnosis Gap
The report highlights a devastating reality: for many, the disease is identified only when it has progressed to advanced stages, such as liver cirrhosis or hepatocellular carcinoma. For those with chronic hepatitis B, fewer than 5% were receiving treatment in 2024. For hepatitis C, the number is similarly underwhelming, with only 20% of the eligible population having accessed treatment since the rollout of curative therapies began.
Stigma and Inequality
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, did not mince words during the summit. "Many people remain undiagnosed and untreated due to stigma, weak health systems, and inequitable access to care," he stated. Stigma continues to drive patients away from clinics, while weak health systems in low- and middle-income countries fail to provide the primary care integration necessary to catch these silent infections early.
Proven Solutions and Models of Success
The report is not merely a catalog of failures; it is a blueprint for success. Countries such as Egypt, Rwanda, the United Kingdom, and Georgia have demonstrated that elimination is not a "pipedream."
- Egypt’s Transformation: Once home to one of the world’s highest rates of hepatitis C, Egypt implemented a massive, state-sponsored screening and treatment campaign, effectively turning the tide on a national epidemic.
- Rwanda and the UK: These nations have shown that sustained political commitment and decentralized health services can successfully bring screening and treatment into the community, rather than relying solely on high-level hospitals.
These success stories share common traits: consistent domestic financing, political will that transcends election cycles, and a willingness to integrate hepatitis testing into standard primary care.
Implications for Global Health Policy
The path forward requires a fundamental shift in how the international community approaches hepatitis. The WHO recommends a multi-pronged strategy to accelerate progress before the 2030 deadline:
1. Integration into Primary Care
Hepatitis services cannot remain siloed. By integrating testing and treatment into primary care, health systems can reach the "hidden" population who may not seek specialized care due to distance, cost, or stigma.
2. Scaling Up Prevention
The disparity in birth-dose vaccination in the African Region is a critical vulnerability. Expanding antiviral prophylaxis to prevent mother-to-child transmission is an essential, cost-effective intervention that must be prioritized.
3. Strengthening Harm Reduction
For hepatitis C, the focus must shift to safe injection practices and harm reduction services. The data shows that failing to protect vulnerable groups like those who inject drugs leads directly to new waves of infection that are harder to contain once they enter the general population.
4. Financial and Political Mobilization
As Dr. Tereza Kasaeva, Director of the WHO Department for HIV, TB, Hepatitis and STIs, emphasized, "Every missed diagnosis and untreated infection… represents a preventable death." This requires not just international aid, but a commitment to reliable domestic financing. Countries must take ownership of their hepatitis response rather than relying on inconsistent external funding.
Conclusion: The Final Countdown
The 2026 Global Hepatitis Report is a mirror reflecting both the resilience of global public health systems and their persistent fragilities. We are in a race against time. The tools—the vaccines, the antiviral medications, and the diagnostic tests—are in our hands. What remains is the task of logistics, political courage, and the moral imperative to ensure that these tools reach the most marginalized populations.
If the world is to meet the 2030 targets, the "business as usual" approach must be abandoned in favor of an accelerated, integrated, and well-funded strategy. The progress of the last decade proves that hepatitis is beatable. The challenge for the next five years is to prove that the world has the collective resolve to finish the job. The lives of millions, and the health of generations to come, depend on the actions taken in the months and years immediately following this summit.
About the Author
